{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:16:46Z","timestamp":1778228206468,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In adult patients with arthritis, use of the tumor necrosis factor (TNF) inhibitor etanercept (ETN) is often associated with a reduction in the utilization of co-medications, particularly steroids. Comparatively little is known about the utilization of co-medications when ETN is initiated in pediatric patients with juvenile idiopathic arthritis (JIA).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study analyzed Canadian longitudinal claims level data spanning January 2007 to April 2017. Data were collated from the IQVIA Private Drug Plan, Ontario Public Drug Plan, and the Quebec Public Drug Plan (R\u00e9gie de l\u2019assurance maladie du Qu\u00e9bec) databases. Patients\u2009&lt;\u200918\u2009years of age were indexed when filling a prescription for ETN between January 2008 and January 2016. Those who met the inclusion and exclusion criteria were assessed for methotrexate (MTX), and prednisone (PRD) use in the 6\u2009months prior to and 12\u2009months following initiation of ETN.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Longitudinal claims data for 330 biologic-naive pediatric patients initiating ETN therapy were included. The majority of patients were female (67%), aged 10\u201317\u2009years (64%), and with a drug history consistent with JIA (96%). Most patients were from Quebec (36%) or Ontario (33%). Dosing of ETN was weight-based with a mean dosage over the first year of 31\u2009mg per week. ETN dosing was relatively consistent over the first year. In total, 222 (67%) patients did not use MTX and 223 (68%) did not use PRD before or after starting ETN. A total of 17% (18\/103) of MTX-treated and 50% (46\/92) of PRD-treated patients discontinued use of those medications upon initiation of ETN treatment. In patients continuing MTX or PRD, significant reductions in the weekly dosage from 14.3 to 6.8\u2009mg per week for MTX and from 56 to 23\u2009mg per week for PRD were observed (<jats:italic>P<\/jats:italic>\u00a0&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study of Canadian claims-level data is the first large prespecified analysis of co-medication utilization following the initiation of ETN therapy in pediatric patients. A decline in both MTX and PRD use and dosage was observed and may be associated with benefits related to safety, tolerability, and overall healthcare costs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-019-0358-x","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:02:46Z","timestamp":1568073766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"17","author":[{"given":"Majed","family":"Khraishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Millson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Woolcott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"issue":"1","key":"358_CR1","first-page":"103","volume":"24","author":"H Schmeling","year":"2006","unstructured":"Schmeling H, Wagner U, Peterson A, Horneff G. Tumor necrosis factor alpha promoter polymorphisms in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2006;24(1):103\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"358_CR2","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/art.24777","volume":"60","author":"EH Giannini","year":"2009","unstructured":"Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794\u2013804.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"358_CR3","first-page":"688","volume":"26","author":"S Nielsen","year":"2008","unstructured":"Nielsen S, Ruperto N, Gerloni V, Simonini G, Cortis E, Lepore L, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26(4):688\u201392.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"358_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","volume":"18","author":"G Horneff","year":"2016","unstructured":"Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"358_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12969-016-0126-0","volume":"14","author":"S Verazza","year":"2016","unstructured":"Verazza S, Davi S, Consolaro A, Bovis F, Insalaco A, Magni-Manzoni S, et al. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol Online J. 2016;14(1):68.","journal-title":"Pediatr Rheumatol Online J."},{"key":"358_CR6","unstructured":"Enbrel Product Monograph; Amgen (Canada)\u00a0 [Updated April 2018. Available from: \n                    https:\/\/www.amgen.ca\/products\/~\/media\/5d0a40b2b8774fb5994190f97daf7fbd.ashx\n                    \n                  ]. Accessed 3 Dec 2018."},{"key":"358_CR7","unstructured":"Khraishi M, Millson B, Woolcott J, Jones H, Marshall L. Etanercept (Enbrel\u00ae) treatment retention in the sub-population of pediatric patients from a retrospective cohort study using Canadian claims-level data. [Poster 2276]. American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP); November 4\u20138, 2017; San Diego, CA, USA 2017."},{"issue":"9","key":"358_CR8","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s10067-018-4141-z","volume":"37","author":"Majed Khraishi","year":"2018","unstructured":"Khraishi M, Ivanovic J, Zhang Y, Millson B, Brabant MJ, Charland K, et al. Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data. Clin Rheumatol. 2018;37(9)2351-360.","journal-title":"Clinical Rheumatology"},{"issue":"4","key":"358_CR9","first-page":"A4257","volume":"58","author":"AC Nilsson","year":"2011","unstructured":"Nilsson AC, Christensen AF, Junker P, Lindegaard HM. Tumour necrosis factor-alpha inhibitors are glucocorticoid-sparing in rheumatoid arthritis. Dan Med Bull. 2011;58(4):A4257.","journal-title":"Dan Med Bull"},{"issue":"4","key":"358_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/rheumatology\/keu339","volume":"54","author":"C Fortunet","year":"2015","unstructured":"Fortunet C, Pers YM, Lambert J, Godfrin-Valnet M, Constant E, Devilliers H, et al. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatology (Oxford). 2015;54(4):672\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"358_CR11","first-page":"303","volume":"34","author":"A Saraux","year":"2016","unstructured":"Saraux A, Rouanet S, Flipo RM, Poncet JC, Fardellone P, Hilliquin P, et al. Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study. Clin Exp Rheumatol. 2016;34(2):303\u201310.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"358_CR12","first-page":"638","volume":"35","author":"C Duquenne","year":"2017","unstructured":"Duquenne C, Wendling D, Sibilia J, Job-Deslandre C, Guillevin L, Benichou J, et al. Glucocorticoid-sparing effect of first-year anti-TNFalpha treatment in rheumatoid arthritis (CORPUS cohort). Clin Exp Rheumatol. 2017;35(4):638\u201346.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"358_CR13","first-page":"1238","volume":"28","author":"LW Moreland","year":"2001","unstructured":"Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001;28(6):1238\u201344.","journal-title":"J Rheumatol"},{"issue":"5","key":"358_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3899\/jrheum.151042","volume":"43","author":"F Iannone","year":"2016","unstructured":"Iannone F, Lopriore S, Bucci R, Lopalco G, Chiala A, Cantarini L, et al. Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings. J Rheumatol. 2016;43(5):911\u20137.","journal-title":"J Rheumatol"},{"issue":"7","key":"358_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/rheumatology\/keu489","volume":"54","author":"L Kearsley-Fleet","year":"2015","unstructured":"Kearsley-Fleet L, Hyrich KL, Davies R, Lunt M, Southwood TR. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2015;54(7):1279\u201385.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"358_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF03347283","volume":"21","author":"F Falcini","year":"1998","unstructured":"Falcini F, Ermini M, Bagnoli F. Bone turnover is reduced in children with juvenile rheumatoid arthritis. J Endocrinol Investig. 1998;21(1):31\u20136.","journal-title":"J Endocrinol Investig"},{"issue":"2","key":"358_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/adc.87.2.93","volume":"87","author":"T Mushtaq","year":"2002","unstructured":"Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and bone health. Arch Dis Child. 2002;87(2):93\u20136.","journal-title":"Arch Dis Child"},{"issue":"Suppl 10","key":"358_CR18","first-page":"S87","volume":"12","author":"PM Woo","year":"1994","unstructured":"Woo PM. Growth retardation and osteoporosis in juvenile chronic arthritis. Clin Exp Rheumatol. 1994;12(Suppl 10):S87\u201390.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"358_CR19","first-page":"831","volume":"34","author":"H Valta","year":"2007","unstructured":"Valta H, Lahdenne P, Jalanko H, Aalto K, Makitie O. Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis. J Rheumatol. 2007;34(4):831\u20136.","journal-title":"J Rheumatol"},{"issue":"11","key":"358_CR20","first-page":"2492","volume":"30","author":"D Simon","year":"2003","unstructured":"Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol. 2003;30(11):2492\u20139.","journal-title":"J Rheumatol"},{"issue":"3","key":"358_CR21","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta12030","volume":"12","author":"J Thornton","year":"2008","unstructured":"Thornton J, Ashcroft D, O'Neill T, Elliott R, Adams J, Roberts C, et al. A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management. Health Technol Assess. 2008;12(3):iii -ix, xi-xiv, 1-208.","journal-title":"Health Technol Assess"},{"key":"358_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1546-0096-12-24","volume":"12","author":"A Soybilgic","year":"2014","unstructured":"Soybilgic A, Tesher M, Wagner-Weiner L, Onel KB. A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America. Pediatr Rheumatol Online J. 2014;12:24.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"358_CR23","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"358_CR24","first-page":"935","volume":"32","author":"Y Kimura","year":"2005","unstructured":"Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32(5):935\u201342.","journal-title":"J Rheumatol"},{"issue":"7485","key":"358_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/bmj.38313.624352.8F","volume":"330","author":"MJ Martel","year":"2005","unstructured":"Martel MJ, Rey E, Beauchesne MF, Perreault S, Lefebvre G, Forget A, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ. 2005;330(7485):230.","journal-title":"BMJ."},{"issue":"5","key":"358_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/j.1537-2995.2007.01614.x","volume":"48","author":"F Gauvin","year":"2008","unstructured":"Gauvin F, Champagne MA, Robillard P, Le Cruguel JP, Lapointe H, Hume H. Long-term survival rate of pediatric patients after blood transfusion. Transfusion (Paris). 2008;48(5):801\u20138.","journal-title":"Transfusion (Paris)"},{"key":"358_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-230X-13-23","volume":"13","author":"J Lachaine","year":"2013","unstructured":"Lachaine J, Yen L, Beauchemin C, Hodgkins P. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol. 2013;13:23.","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"358_CR28","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","volume":"21","author":"U Kopylov","year":"2015","unstructured":"Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin Cancer in patients with IBD treated with Immunomodulators and biologics: a Quebec claims database study. Inflamm Bowel Dis. 2015;21(8):1847\u201353.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"358_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/jmv.24968","volume":"90","author":"M Steben","year":"2018","unstructured":"Steben M, Ouhoummane N, Rodier C, Sinyavskaya L, Brassard P. The early impact of human papillomavirus vaccination on anogenital warts in Quebec. Canada J Med Virol. 2018;90(3):592\u20138.","journal-title":"Canada J Med Virol"},{"issue":"1","key":"358_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jval.2017.06.012","volume":"21","author":"Wendy Dobson-Belaire","year":"2018","unstructured":"Dobson-Belaire W, Goodfield J, Borrelli R, Liu FF, Khan ZM. Identifying psoriasis and psoriatic arthritis patients in retrospective databases when diagnosis codes are not available:\u00a0a validation study comparing medication\/prescriber visit\u2013based algorithms with diagnosis codes. Value Health. 2018;21(1):110\u20136.","journal-title":"Value in Health"},{"issue":"1","key":"358_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12519-015-0009-3","volume":"12","author":"X Hu","year":"2016","unstructured":"Hu X, Yuan F, Zhang J, Yin L, Li BR, Jin YL. Effect of etanercept on refractory systemic-onset juvenile idiopathic arthritis. World J Pediatr. 2016;12(1):96\u2013102.","journal-title":"World J Pediatr"},{"issue":"5","key":"358_CR32","first-page":"807","volume":"27","author":"R Seror","year":"2009","unstructured":"Seror R, Dougados M, Gossec L. Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol. 2009;27(5):807\u201313.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"358_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12969-017-0138-4","volume":"15","author":"PC Hissink Muller","year":"2017","unstructured":"Hissink Muller PC, Brinkman DM, Schonenberg D, Koopman-Keemink Y, Brederije IC, Bekkering WP, et al. A comparison of three treatment strategies in recent onset non-systemic juvenile idiopathic arthritis: initial 3-months results of the BeSt for kids-study. Pediatr Rheumatol Online J. 2017;15(1):11.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"10","key":"358_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00296-008-0563-2","volume":"28","author":"N Tzaribachev","year":"2008","unstructured":"Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Rheumatol Int. 2008;28(10):1031\u20134.","journal-title":"Rheumatol Int"},{"issue":"6","key":"358_CR35","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/rheumatology\/keq432","volume":"50","author":"FH Prince","year":"2011","unstructured":"Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch arthritis and biologicals in children register. Rheumatology (Oxford). 2011;50(6):1131\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"358_CR36","doi-asserted-by":"publisher","unstructured":"Alexeeva E, Dvoryakovskaya T, Denisova R, Sleptsova T, Isaeva K, Chomahidze A, et al. Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate. Pediatr Neonatol. 2019. \n                    https:\/\/doi.org\/10.1016\/j.pedneo.2019.02.003\n                    \n                  . [Epub ahead of print]","DOI":"10.1016\/j.pedneo.2019.02.003"},{"issue":"1","key":"358_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","volume":"20","author":"J Swart","year":"2018","unstructured":"Swart J, Giancane G, Horneff G, Magnusson B, Hofer M. Alexeeva capital Ie C, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018;20(1):285.","journal-title":"Arthritis Res Ther"},{"key":"358_CR38","unstructured":"Methotrexate Canadian product monograph. 2017. Available from:\u00a0\n                    https:\/\/www.pfizer.ca\/sites\/default\/files\/201908\/Methotrexate_Injection_PM_E_224776_08July2019.pdf\n                    \n                  . Accessed 3 Dec 2018."},{"issue":"8","key":"358_CR39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1445-5994.2009.02059.x","volume":"40","author":"DH White","year":"2010","unstructured":"White DH, Chapman PT, O'Donnell JL, James J, Frampton C, Stamp LK. Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. Intern Med J. 2010;40(8):561\u20135.","journal-title":"Intern Med J"},{"issue":"8","key":"358_CR40","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/rheumatology\/kez048","volume":"58","author":"Lianne Kearsley-Fleet","year":"2019","unstructured":"Kearsley-Fleet L, Vicente Gonzalez L, Steinke D, Davies R, De Cock D, Baildam E, et al. Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2019. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kez048\n                    \n                  . [Epub ahead of print]","journal-title":"Rheumatology"},{"issue":"1","key":"358_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5114\/aoms.2010.13501","volume":"6","author":"W Umlawska","year":"2010","unstructured":"Umlawska W, Prusek-Dudkiewicz A. Growth retardation and delayed puberty in children and adolescents with juvenile idiopathic arthritis. Arch Med Sci. 2010;6(1):19\u201323.","journal-title":"Arch Med Sci"},{"issue":"1","key":"358_CR42","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13075-016-1109-8","volume":"18","author":"T Beukelman","year":"2016","unstructured":"Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, et al. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2016;18(1):210.","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"358_CR43","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.semarthrit.2012.10.006","volume":"42","author":"WJ Ungar","year":"2013","unstructured":"Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum. 2013;42(6):597\u2013618.","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"358_CR44","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/acr.22903","volume":"68","author":"NJ Luca","year":"2016","unstructured":"Luca NJ, Burnett HF, Ungar WJ, Moretti ME, Beukelman T, Feldman BM, et al. Cost-effectiveness analysis of first-line treatment with biologic agents in Polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2016;68(12):1803\u201311.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"358_CR45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/acr.20337","volume":"63","author":"WJ Ungar","year":"2011","unstructured":"Ungar WJ, Costa V, Hancock-Howard R, Feldman BM, Laxer RM. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2011;63(1):111\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"358_CR46","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10198-012-0431-6","volume":"14","author":"I Lekander","year":"2013","unstructured":"Lekander I, Borgstr\u00f6m F, Lysholm J, van Vollenhoven RF, Lindblad S, Geborek P, et al. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. Eur J Health Econ. 2013;14(6):863\u201373.","journal-title":"Eur J Health Econ"},{"issue":"7","key":"358_CR47","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/rheumatology\/keu460","volume":"54","author":"MK Kvamme","year":"2015","unstructured":"Kvamme MK, Lie E, Uhlig T, Moger TA, Kvien TK, Kristiansen IS. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies. Rheumatology (Oxford). 2015;54(7):1226\u201335.","journal-title":"Rheumatology (Oxford)"},{"key":"358_CR48","doi-asserted-by":"publisher","first-page":"581409","DOI":"10.1155\/2013\/581409","volume":"2013","author":"C Said","year":"2013","unstructured":"Said C, Coleiro B, Zarb Adami M, Azzopardi LM, Serracino IA. Cost effectiveness of TNF-alpha inhibitors in rheumatoid arthritis. Int J Inflam. 2013;2013:581409.","journal-title":"Int J Inflam"},{"key":"358_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1546-0096-7-13","volume":"7","author":"AO Hersh","year":"2009","unstructured":"Hersh AO, Pang S, Curran ML, Milojevic DS, von Scheven E. The challenges of transferring chronic illness patients to adult care: reflections from pediatric and adult rheumatology at a US academic center. Pediatr Rheumatol Online J. 2009;7:13.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"2","key":"358_CR50","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.pcl.2005.01.008","volume":"52","author":"LB Tucker","year":"2005","unstructured":"Tucker LB, Cabral DA. Transition of the adolescent patient with rheumatic disease: issues to consider. Pediatr Clin N Am. 2005;52(2):641\u201352 viii.","journal-title":"Pediatr Clin N Am"},{"issue":"1","key":"358_CR51","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12969-017-0176-y","volume":"15","author":"CG Anelli","year":"2017","unstructured":"Anelli CG, Amorim ALM, Osaku FM, Terreri MT, Len CA, Reiff A. Challenges in transitioning adolescents and young adults with rheumatologic diseases to adult Care in a Developing Country - the Brazilian experience. Pediatr Rheumatol Online J. 2017;15(1):47.","journal-title":"Pediatr Rheumatol Online J."},{"key":"358_CR52","unstructured":"American College of Rheumatology. Pediatric to adult rheumatology care transition. 2018. Available from: \n                    https:\/\/www.rheumatology.org\/Practice-Quality\/Pediatric-to-Adult-Rheumatology-Care-Transition\n                    \n                  . Accessed 3 Dec 2018."},{"issue":"2","key":"358_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3111\/13696998.2015.1099538","volume":"19","author":"J Harnett","year":"2016","unstructured":"Harnett J, Wiederkehr D, Gerber R, Gruben D, Koenig A, Bourret J. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. J Med Econ. 2016;19(2):91\u2013102.","journal-title":"J Med Econ"},{"key":"358_CR54","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2147\/PPA.S137206","volume":"11","author":"U Lathia","year":"2017","unstructured":"Lathia U, Ewara EM, Nantel F. Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis. Patient preference and adherence. 2017;11:1133\u201342.","journal-title":"Patient preference and adherence"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-019-0358-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T09:03:07Z","timestamp":1599728587000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-019-0358-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1186\/s12969-019-0358-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]},"assertion":[{"value":"13 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N\/A","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MK is an advisor for Pfizer and Amgen.BM is an employee of IQVIA and was contracted by Pfizer in connection with the development of this manuscript.JW is an employee of Pfizer.HJ was an employee of Pfizer\u00a0when this study was conducted.LM was an employee of Pfizer when this study was conducted.NR has received honoraria for consultancies or speaker bureaus (<\u200910.000 USD each) from the following pharmaceutical companies in the past 3\u2009years: Ablynx, AbbVie, Astrazeneca-Medimmune, Biogen, Boehringer, Bristol Myers and Squibb, Eli-Lilly, EMD Serono, Glaxo Smith and Kline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, SanofiServier, Sinergie, Sobi and Takeda.The Gaslini Hospital, where NR works as full-time public employee, has received contributions (>\u200910.000 USD each) from the following industries in the last 3\u2009years: BMS, Eli-Lilly, GlaxoSmithKline, F Hoffmann-La Roche, Janssen, Novartis, Pfizer, Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}